Obicetrapib: how it works, status and trials
Phase 3 (PREVAIL outcome trial ongoing)PillLowering LDL cholesterol
Obicetrapib is an investigational daily pill that blocks CETP, a protein that moves cholesterol from HDL onto apoB particles such as LDL. Blocking it lowers LDL and raises HDL. Its outcome trial (PREVAIL) is ongoing, and it is not approved.
In technical terms: Blocks transfer of cholesteryl ester from HDL to apoB particles; LDL-C, apoB and Lp(a) fall and HDL-C rises.
The highlighted badge marks where Obicetrapib acts. Open the full map or compare every therapy.
At a glance
- Acts on
- CETP · blood
- How it is given
- Oral small molecule · daily
- What the main trial found
- LDL-C −32.6 pp (BROADWAY)
- Status (curated October 25, 2026)
- Phase 3 (PREVAIL outcome trial ongoing)
Trials and registry status
From ClinicalTrials.gov, PubMed and openFDA, refreshed monthly. Last run October 27, 2026.
Obicetrapib from NewAmsterdam / Menarini
Stage: Phase 3. 7 active of 29 registered trials. 3 new papers in the last 31 days.
- PREVAIL (NCT05202509): active not recruiting, primary completion 2026-11
Recent changes
- October 25, 2026: PMID 42920302: Effect of Obicetrapib on Glycaemia and New-Onset Diabetes: Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of CETP Inhibit
- October 25, 2026: PMID 42866070: Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition.
Evidence
- BROADWAY (PubMed 40337982)
Common questions
How does Obicetrapib work?
Obicetrapib is an investigational daily pill that blocks CETP, a protein that moves cholesterol from HDL onto apoB particles such as LDL. Blocking it lowers LDL and raises HDL. Its outcome trial (PREVAIL) is ongoing, and it is not approved. In technical terms: Blocks transfer of cholesteryl ester from HDL to apoB particles; LDL-C, apoB and Lp(a) fall and HDL-C rises. It acts on CETP · blood.
How much does Obicetrapib lower cholesterol or other lipids?
LDL-C −32.6 pp (BROADWAY). Individual results differ, and a clinician can say what to expect for one person.
Is Obicetrapib approved, and what is the status?
Phase 3 (PREVAIL outcome trial ongoing) (curated October 25, 2026). Registry stage as of October 27, 2026: Obicetrapib, Phase 3.
How is Obicetrapib taken?
Oral small molecule · daily.
Read more
Related therapies
- Statins: Approved (generic)
- Bempedoic acid (Nexletol, Nexlizet): Approved 2020
- Ezetimibe (Zetia): Approved (generic)
- Bile acid sequestrants (colesevelam): Approved (generic)
Educational, not medical advice. Mechanism and status text curated October 25, 2026; registry data refreshed October 27, 2026. Registries can lag company announcements. Effects are placebo-adjusted results from the main published trial, not head-to-head comparisons. Investigational agents are available only in clinical trials. Preval Health does not practice medicine; licensed clinicians in a partner network provide care. If you have chest pain or signs of a stroke, call 911.